Global Irritable Bowel Syndrome Treatment Market Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Irritable Bowel Syndrome Treatment Market


The global Irritable Bowel Syndrome Treatment market size is projected to reach US$ 3.24 billion by 2026, from US$ 1.82 billion in 2020, at a CAGR of 10.1% during 2021-2026. Rising prevalence of target disease, coupled with increasing uptake of drugs for the same, is driving the market.

Furthermore, rising commercialization of existing products in different regions is expected to accelerate growth over the forecast period. Increasing adoption of Linzess in U.S., Europe, and Japan has been significantly contributing to revenue growth. Linzess was approved in China in January 2019, which is further expected to give the market a boost.

The market mostly remains underserved, with a considerable number of opportunities for pharmaceutical companies to address several unmet needs in this therapy area. There are a few promising products currently under clinical trials, which can further accelerate growth. Product sales are projected to grow significantly over the forecast period, mainly due to increasing prevalent population and commercialization of novel drugs to treat Constipation-predominant irritable bowel syndrome (IBS).

Irritable bowel syndrome is one of the most common functional gastrointestinal disorders, with an estimated global prevalence rate of 10-15%. According to the International Foundation for Gastrointestinal Disorders (IFFGD) in 2016, it was estimated that IBS affects around 25-45 million in the U.S. About 2 in 3 IBS patients are female and most people with this condition are under the age of 50.

The exact cause of symptoms is unknown and symptoms may result from a disturbance in the way the brain, nervous system, and gut interact. This can lead to changes in normal bowel sensation and movement. According to a survey by IFFGD, approximately 2,000 patients with IBS reported that diagnosis of their conditions was typically made 6.6 years after their symptoms began.

Approximately 20-40% of all patient visits to gastroenterologists are due to symptoms of irritable bowel syndrome. Yet numerous people remain unaware and undiagnosed that their symptoms indicate a medically recognized disorder. As a result of this, numerous awareness campaigns are being organized to raise awareness about the condition.

For instance, The IBS Network in U.K. ran several activities throughout April in 2018, to overcome the stigma surrounding the illness. The campaign was targeted at people living with IBS and physicians who work to help those fighting the symptoms. These campaigns and initiatives are expected to raise awareness about the disorder and encourage patients to seek treatment for their conditions. This, in turn, is expected to accelerate IBS treatment market growth.

Market Segmentation, Outlook & Viewpoint: Global Irritable Bowel Syndrome Treatment Market

Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
IBS-C
  
Linzess/Constella
  
Amitiza
  
Others
  
IBS-D
  
Xifaxan
  
Viberzi
  
Others

Product Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)

  
Xifaxan
  
Linzess/Constella
  
Viberzi
  
Amitiza
  
Others

Key Players, Recent Developments & Regional Insights: Global Irritable Bowel Syndrome Treatment Market

Leading products developed for the treatment of symptoms of irritable bowel syndrome includeXifaxan, Linzess/Constella, Viberzi, and Amitiza. Linzess/Constella (Linaclotide) was estimated to be the largest revenue generating product segment in 2018 owing to factors such as rising adoption of the product in major regions such as U.S., U.K., Germany, Spain, Italy, and Japan. Furthermore, Linzess witnessed a significant growth rate in Japan in 2018.

The Linzess/Constella segment is estimated to register the fastest growth over the course of the forecast period. Linaclotide is marketed by Ironwood and Allergan in U.S. as Linzess and is marketed by Allergan in Europe under the brand name Constella. In Japan and China, Astellas and AstraZeneca have the exclusive rights to develop and market linaclotide as Linzess respectively.

Regional Insights

North America was the largest revenue generating region in 2018 and is expected to exhibit the same trend over the forecast period. The region held the dominant share due to the resence of key market players, a well-established healthcare infrastructure, greater patient awareness, and strong presence of novel products.

Europe is estimated to be the fastest growing region over the forecast period due to the presence of a large target population and rising commercialization of IBS products in the region. Furthermore, increasing initiatives in the region to raise awareness about the condition is likely to accelerate market growth.
Irritable Bowel Syndrome Treatment Market Share Insights

Some of the key players in the market are Ironwood Pharmaceuticals, Inc.; Allergan; Astellas Pharma, Inc.; Takeda Pharmaceutical Company Limited AstraZeneca; Sebela Pharmaceuticals Inc.; Synergy Pharmaceuticals In.Bausch Health; Synthetic Biologics, Inc.; and Ardelyx. Key players have been adopting different strategies such as mergers and acquisitions to increase their market share. For instance, Bausch Health acquired Salix Pharmaceuticals in April 2015 to expand its portfolio with a focus on gastrointestinal drugs.

Players are also focusing on launching their products in different regions to expand their market presence. For instance, in January 2019, Ironwood Pharmaceuticals and AstraZeneca received marketing approval for Linzess in China with an aim to strengthen its position in the market.

Key Insights Covered: Global Irritable Bowel Syndrome Treatment Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Irritable Bowel Syndrome Treatment industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Irritable Bowel Syndrome Treatment industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Irritable Bowel Syndrome Treatment industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Irritable Bowel Syndrome Treatment industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Irritable Bowel Syndrome Treatment industry.

Research Methodology: Global Irritable Bowel Syndrome Treatment Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other